Jacob graduated from the University of Maryland with degrees in journalism and biology. He's previously reported on M&A at TheDeal, politics at McClatchy DC and education research at Education Week. His main interests include RuPaul's Drag Race, anything from the McDonalds menu and strong shoe game. He has loud opinions about avocado toast and Vine ending.
1223 articles by Jacob Bell
-
Denali drug for rare brain disease disappoints investors
July 26, 2021 -
Major health centers, insurers push back against Aduhelm
July 15, 2021 -
Biohaven CEO on migraine drug's fast launch, TikTok ads and battling big pharma
July 14, 2021 -
Bluebird resumes marketing gene therapy in Europe
July 9, 2021 -
Gene therapy for sickle cell disease: progress and competition
July 8, 2021 -
FDA knocks back diabetes prevention drug, crushing its maker's shares
July 6, 2021 -
GSK returns to brain drugs with major biotech deal
July 2, 2021 -
Pfizer's neuroscience spinout scores in schizophrenia
June 29, 2021 -
European regulators push 8 drugs toward approval, including controversial anemia pill
June 25, 2021 -
With Alzheimer's drugs in focus, Bristol Myers rejoins the hunt
June 24, 2021 -
FDA documents show how controversial Alzheimer's drug decision was reached
June 22, 2021 -
A year after getting UniQure's gene therapy, hemophilia patients are still doing better
June 22, 2021 -
Public Citizen calls for top FDA officials to resign following Alzheimer's drug approval
June 16, 2021 -
Biogen gene therapy deal has yet to bear fruit
June 15, 2021 -
Moderna founder raises another $2B to fuel new startups
June 14, 2021 -
Vertex stops work on second rare disease drug after study results disappoint
June 10, 2021 -
A first-of-its-kind Alzheimer's drug raises heavy questions around who will and won't get it
June 8, 2021 -
In historic move, FDA approves a closely watched and controversial Alzheimer's drug
June 7, 2021 -
Biotech venture capital still booming as venBio raises another $550M
June 3, 2021 -
Alkermes prepares for uncertain launch as FDA finally clears schizophrenia drug
June 1, 2021 -
A biotech backs off NASH after trial failure
May 24, 2021 -
Bluebird's next gene therapy gets backing from European regulator
May 21, 2021 -
In the midst of a 'strategic shift,' Voyager loses CEO and R&D head
May 20, 2021 -
FDA approval sets stage for a showdown between Alexion and Apellis
May 17, 2021 -
Third Rock launches biotech targeting 'notoriously difficult' DNA regulators
May 13, 2021